Continuous Monitoring with the Corsano CardioWatch 287-2B in Haemato-Oncology Patients for Early Deterioration Detection

Rationale
Patients with haematological malignancies undergoing inpatient treatment, such as immunochemotherapy or stem cell transplantation, are at increased risk for rapid clinical deterioration. Complications like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can occur unpredictably, and delayed detection may lead to poorer outcomes and unplanned ICU admissions.

Standard early warning scores (e.g., NEWS2, qSOFA) depend on intermittent manual measurements and are limited by low specificity, delayed responsiveness, and variable clinical application. There is a pressing need for real-time, non-invasive monitoring that can detect early physiological changes preceding deterioration.

The Corsano CardioWatch 287-2B offers continuous tracking of vital signs—including heart rate, respiratory rate, oxygen saturation, wrist temperature (for estimating core body temperature), and cuffless blood pressure equivalents. When paired with Corsano’s algorithmic tools (Cor-NEWS2, Cor-EWS, Cor-EWS-AI), the system enables early risk stratification and trend-based alerts.

Study Objectives
This haemato-oncology substudy builds on the CORSEP trial framework and aims to:
• Evaluate the feasibility of using Corsano CardioWatch 287-2 for continuous monitoring in hematology inpatients.
• Validate the Cor-NEWS2, Cor-EWS, and Cor-EWS-AI algorithms for early detection of clinical deterioration in a hematological population.
• Assess the usability and clinical integration of wearable technology in routine hematology care.
• Compare the predictive performance of this scoring system to conventional scoring systems, including NEWS2, MEWS, and qSOFA.

Study Design
This is a prospective, single-center observational study conducted at Universitätsmedizin Greifswald. The study focuses on inpatients treated within the haemato-oncology department, including patients undergoing immunochemotherapy or stem cell transplantation. Participants wear the Corsano CardioWatch 287-2 continuously throughout hospitalization, while medical care is provided according to usual care protocols and without access to real-time wearable data.
The study is designed to mirror the methodology of the CORSEP trial in surgical patients but targets a distinct clinical cohort with hematological malignancies.

Inclusion Criteria
• Adults aged ≥18 years
• Diagnosed with a hematological malignancy
• Admitted to the haemato-oncology ward
• Capable of providing informed consent

Exclusion Criteria
• Inability to provide informed consent
• Inability to wear the CardioWatch 287-2 (due to skin injury, amputation, allergic reaction)
• Severe cognitive impairment or palliative status

Current Status
The study is actively recruiting. As of the latest update, 8 haemato-oncology patients have been enrolled. Recruitment is ongoing and expands Corsano’s real-time monitoring capabilities to a new patient population within the same institutional infrastructure as the CORSEP trial. The study will continue until 50 participants have been included.

Timeline
Status: Recruiting patients
Start Date: Mid-2024
Estimated Duration: 18 months

Study center
Universitätsmedizin Greifswald, Germany

Interested in our Trial Programme?

Corsano Cardiowatch Bracelets enable continuous monitoring with multiple algorithms. Corsano is working closely with cardiologists, scientists, hospitals, patients, and research organisations.  Scientific research demonstrates the legitimacy of Cardiowatch 287 algorithms. 

We are currently performing pilots with selected clients. Contact us if you want to know more!

Corsano CardioWatch is a wrist worn medical grade multi sensor bracelet to capture up to 19 vital parameters. Primary use cases are 24/7 continuous clinical trials and remote patient monitoring.  
 
The bracelet monitor offers flexibility to set data collection intervals by minute, by second or 25Hz, 32 Hz or 128 Hz. We measure Heart Rate, RR intervals, Breathing Rate, A-Fib detection, Skin Temperature, Activity and Sleep. SpO2, Core Body Temperature, ECG and Blood Pressure are in development.  
 
Clinical accuracy is paramount for us. In addition to third parties' algorithms, i.e. from Philips, we run our proprietary algorithms to realize superior data accuracy. Corsano technology has been clinically validated in major academic hospitals. The bracelet is manufactured under ISO 13485 and CE-MDR compliance. The process for FDA Clearance has started. 
 
Our end-to-end solution consists of light-weight and comfortable bracelets with a patient research portal. We have developed and produced over 200’000 devices. The Corsano platform has been optimized on connections, data buffers and battery life up to 15 days. We offer access to raw continuous high frequency data through API and cloud-to-cloud solutions. 
 

The founders of Corsano Health have over 100 years of experience in the Swiss Watch industry, with deep experience about ergonomic design and materials for wearables that are worn 24/7.  

Rationale
Patients with haematological malignancies undergoing inpatient treatment, such as immunochemotherapy or stem cell transplantation, are at increased risk for rapid clinical deterioration. Complications like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can occur unpredictably, and delayed detection may lead to poorer outcomes and unplanned ICU admissions.

Standard early warning scores (e.g., NEWS2, qSOFA) depend on intermittent manual measurements and are limited by low specificity, delayed responsiveness, and variable clinical application. There is a pressing need for real-time, non-invasive monitoring that can detect early physiological changes preceding deterioration.

The Corsano CardioWatch 287-2B offers continuous tracking of vital signs—including heart rate, respiratory rate, oxygen saturation, wrist temperature (for estimating core body temperature), and cuffless blood pressure equivalents. When paired with Corsano’s algorithmic tools (Cor-NEWS2, Cor-EWS, Cor-EWS-AI), the system enables early risk stratification and trend-based alerts.

Study Objectives
This haemato-oncology substudy builds on the CORSEP trial framework and aims to:
• Evaluate the feasibility of using Corsano CardioWatch 287-2 for continuous monitoring in hematology inpatients.
• Validate the Cor-NEWS2, Cor-EWS, and Cor-EWS-AI algorithms for early detection of clinical deterioration in a hematological population.
• Assess the usability and clinical integration of wearable technology in routine hematology care.
• Compare the predictive performance of this scoring system to conventional scoring systems, including NEWS2, MEWS, and qSOFA.

Study Design
This is a prospective, single-center observational study conducted at Universitätsmedizin Greifswald. The study focuses on inpatients treated within the haemato-oncology department, including patients undergoing immunochemotherapy or stem cell transplantation. Participants wear the Corsano CardioWatch 287-2 continuously throughout hospitalization, while medical care is provided according to usual care protocols and without access to real-time wearable data.
The study is designed to mirror the methodology of the CORSEP trial in surgical patients but targets a distinct clinical cohort with hematological malignancies.

Inclusion Criteria
• Adults aged ≥18 years
• Diagnosed with a hematological malignancy
• Admitted to the haemato-oncology ward
• Capable of providing informed consent

Exclusion Criteria
• Inability to provide informed consent
• Inability to wear the CardioWatch 287-2 (due to skin injury, amputation, allergic reaction)
• Severe cognitive impairment or palliative status

Current Status
The study is actively recruiting. As of the latest update, 8 haemato-oncology patients have been enrolled. Recruitment is ongoing and expands Corsano’s real-time monitoring capabilities to a new patient population within the same institutional infrastructure as the CORSEP trial. The study will continue until 50 participants have been included.

Timeline
Status: Recruiting patients
Start Date: Mid-2024
Estimated Duration: 18 months

Study center
Universitätsmedizin Greifswald, Germany

Interested in our Trial Programme?

Corsano Cardiowatch Bracelets enable continuous monitoring with multiple algorithms. Corsano is working closely with cardiologists, scientists, hospitals, patients, and research organisations.  Scientific research demonstrates the legitimacy of Cardiowatch 287 algorithms. 

We are currently performing pilots with selected clients. Contact us if you want to know more!

Corsano CardioWatch is a wrist worn medical grade multi sensor bracelet to capture up to 19 vital parameters. Primary use cases are 24/7 continuous clinical trials and remote patient monitoring.  
 
The bracelet monitor offers flexibility to set data collection intervals by minute, by second or 25Hz, 32 Hz or 128 Hz. We measure Heart Rate, RR intervals, Breathing Rate, A-Fib detection, Skin Temperature, Activity and Sleep. SpO2, Core Body Temperature, ECG and Blood Pressure are in development.  
 
Clinical accuracy is paramount for us. In addition to third parties' algorithms, i.e. from Philips, we run our proprietary algorithms to realize superior data accuracy. Corsano technology has been clinically validated in major academic hospitals. The bracelet is manufactured under ISO 13485 and CE-MDR compliance. The process for FDA Clearance has started. 
 
Our end-to-end solution consists of light-weight and comfortable bracelets with a patient research portal. We have developed and produced over 200’000 devices. The Corsano platform has been optimized on connections, data buffers and battery life up to 15 days. We offer access to raw continuous high frequency data through API and cloud-to-cloud solutions. 
 

The founders of Corsano Health have over 100 years of experience in the Swiss Watch industry, with deep experience about ergonomic design and materials for wearables that are worn 24/7.